Clinicopathologic characteristics and survival analysis of primary large B-cell lymphoma of the central nervous system
10.3760/cma.j.cn121090-20231126-00278
- VernacularTitle:原发中枢神经系统大B细胞淋巴瘤临床病理特点及生存分析
- Author:
Qifan XU
1
;
Rong SHEN
;
Yige SHEN
;
Yiwen CAO
;
Ying QIAN
;
Pengpeng XU
;
Shu CHENG
;
Li WANG
;
Weili ZHAO
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，医学基因组学国家重点实验室，上海血液学研究所，上海 200025
- Keywords:
Lymphoma, large B-cell, diffuse;
Central nervous system;
Bruton tyrosine kinase;
Mutation;
Prognosis
- From:
Chinese Journal of Hematology
2024;45(5):481-487
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively analyze the clinical and pathologic characteristics, response to treatment, survival, and prognosis of patients with primary large B-cell lymphoma of the central nervous system (PCNSLBCL) .Methods:Clinical and pathologic data of 70 patients with PCNSLBCL admitted to Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from December 2010 to November 2022 were collected for retrospective analysis. Survival analysis was performed using the Kaplan-Meier method and log-rank test, and prognosis analysis was conducted using the Cox proportional hazards model.Results:Among 70 patients with PCNSLBCL, complete remission (CRs) were achieved in 49 (70.0% ) and partial remission in 4 (5.7% ) after the first-line induction therapy; the overall remission rate was 75.7%. The 2-year progression-free survival (PFS) rate was 55.8% and the median progression-free survival (mPFS) time was 35.9 months, whereas the 2-year overall survival (OS) rate was 79.1% with a median OS time not reached. After CR induced by first-line therapy, cumulative incidence of relapse (CIR) was lower in patients who had received auto-HSCT than in those who had not received consolidation therapy ( P=0.032), whose 2-year PFS rate was 54.4% and mPFS time was 35.9 months; comparatively, the 2-year PFS rate in patients having received oral maintenance of small molecule drugs reached 84.4% with a mPFS time of 79.5 months ( P=0.038). Multivariant analysis demonstrated that Class 3 in the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model is an independent adverse prognostic factor of OS in patients with PCNSLBCL ( HR=3.127, 95% CI 1.057-9.253, P=0.039) . Conclusions:In patients with PCNSLBCL achieving CR after the first-line induction therapy, auto-HSCT as consolidation therapy would lead to a decreased CIR, and PFS time could be prolonged by oral maintenance of small molecule drugs. Class 3 MSKCC prognostic model is independently associated with poorer OS.
